| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $123,400 | 3 | 75 |
Sells | $10,268 | 1 | 25 |
| CHRISTOPHER RICHARD | Chief Executive Officer | 2 | $118,392 | 0 | $0 | $118,392 |
| TURKEL CATHERINE C. | director | 1 | $5,008 | 0 | $0 | $5,008 |
| Carle Vanessa | Secretary | 0 | $0 | 1 | $10,268 | $-10,268 |
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Over the last 12 months, insiders at Lexaria Bioscience Corp. have bought $123,400 and sold $10,268 worth of Lexaria Bioscience Corp. stock.
On average, over the past 5 years, insiders at Lexaria Bioscience Corp. have bought $103,158 and sold $10,268 worth of stock each year.
Highest buying activity among insiders over the last 12 months: CHRISTOPHER RICHARD (Chief Executive Officer) — $118,392. TURKEL CATHERINE C. (director) — $5,008.
The last purchase of 27,172 shares for transaction amount of $67,175 was made by CHRISTOPHER RICHARD (Chief Executive Officer) on 2024‑12‑03.
| 2024-12-03 | CHRISTOPHER RICHARD | Chief Executive Officer | 27,172 0.1442% | $2.47 | $67,175 | -47.22% | ||
| 2024-12-02 | CHRISTOPHER RICHARD | Chief Executive Officer | 22,828 0.1328% | $2.24 | $51,217 | -36.16% | ||
| 2024-08-12 | TURKEL CATHERINE C. | director | 1,600 0.0097% | $3.13 | $5,008 | -44.65% | ||
| 2024-07-31 | Sale | Carle Vanessa | Secretary | 2,567 0.0177% | $4.00 | $10,268 | -54.52% | |
| 2023-02-09 | TURKEL CATHERINE C. | director | 1,500 0.0253% | $2.84 | $4,267 | -55.28% | ||
| 2022-10-14 | Downey Gregory | Chief Financial Officer | 121 0.002% | $2.09 | $253 | +1.66% | ||
| 2022-10-13 | BUNKA CHRISTOPHER | Chief Executive Officer | 16,600 0.275% | $2.10 | $34,860 | +0.47% | ||
| 2022-10-12 | BUNKA CHRISTOPHER | Chief Executive Officer | 21,900 0.3658% | $1.99 | $43,537 | +7.00% | ||
| 2018-05-30 | Sale | McKechnie William Edward | 47,900 0.0843% | $1.90 | $91,011 |
| CHRISTOPHER RICHARD | Chief Executive Officer | 50000 0.2566% | $47,275.00 | 2 | 0 | |
| TURKEL CATHERINE C. | director | 3100 0.0159% | $2,931.05 | 2 | 0 | <0.0001% |
| Carle Vanessa | Secretary | 0 0% | $0 | 0 | 1 | |
| McKechnie William Edward | 287838 1.4773% | $272,150.83 | 0 | 1 | ||
| BUNKA CHRISTOPHER | Chief Executive Officer | 254412 1.3057% | $240,546.55 | 2 | 0 | +3.73% |
| Downey Gregory | Chief Financial Officer | 1954 0.01% | $1,847.51 | 1 | 0 | +1.66% |
$53,490,060 | 55 | 19.35% | $19.52M | |
$226,127 | 22 | -27.62% | $16.85M | |
$555,628 | 21 | 43.52% | $16.67M | |
$114,405,653 | 19 | -5.40% | $15.93M | |
$112,810,270 | 18 | -1.20% | $19.24M | |
$122,973 | 15 | -26.96% | $19.25M | |
$79,536,861 | 15 | -6.81% | $20.56M | |
$1,199,157 | 14 | 7.52% | $19.15M | |
$39,336,371 | 14 | -17.87% | $17.89M | |
$389,864 | 11 | 12.52% | $19.33M | |
$20,715,938 | 10 | -42.51% | $19.33M | |
$11,777,042 | 10 | -11.94% | $17.1M | |
$70,584,874 | 10 | 3.97% | $14.26M | |
$309,830 | 10 | -55.78% | $19.56M | |
$2,889,596 | 6 | -43.43% | $14.58M | |
$2,060,158 | 5 | -21.35% | $16.69M | |
Lexaria Bioscience Corp. (LEXX) | $82,917 | 4 | -11.54% | $18.42M |
$31,190 | 2 | -14.18% | $20.35M | |
$19,863 | 1 | 144.27% | $15.51M |
| Increased Positions | 9 | +30% | 281,793 | +18.68% |
| Decreased Positions | 11 | -36.67% | 500,255 | -33.17% |
| New Positions | 2 | New | 130,407 | New |
| Sold Out Positions | 5 | Sold Out | 492,965 | Sold Out |
| Total Postitions | 28 | -6.67% | 1M | -14.48% |
| Armistice Capital, Llc | $547.00 | 2.42% | 460,000 | +460,000 | New | 2024-12-31 |
| Invenomic Capital Management Lp | $489.00 | 2.16% | 410,731 | -65,042 | -13.67% | 2024-12-31 |
| Geode Capital Management, Llc | $198.00 | 0.88% | 166,679 | +16,288 | +10.83% | 2024-12-31 |
| Vanguard Group Inc | $152.00 | 0.67% | 127,433 | +18,411 | +16.89% | 2024-12-31 |
| Raymond James Financial Inc | $72.00 | 0.32% | 60,640 | +60,640 | New | 2024-12-31 |
| Raymond James Financial Services Advisors, Inc. | $53.00 | 0.24% | 44,900 | -3,900 | -7.99% | 2024-09-30 |
| State Street Corp | $47.00 | 0.21% | 39,301 | 0 | 0% | 2024-12-31 |
| Wealth Enhancement Advisory Services, Llc | $37.00 | 0.16% | 30,959 | +2,086 | +7.22% | 2025-03-31 |
| Byrne Asset Management Llc | $34.00 | 0.15% | 28,905 | +15,905 | +122.35% | 2025-03-31 |
| Blackrock, Inc. | $33.00 | 0.14% | 27,445 | 0 | 0% | 2025-03-31 |